Importance of interleukin-1 and interleukin-1 receptor antagonist in short-term glucose sensor function in vivo

Journal of Diabetes Science and Technology

Volumn 4, Issue 5, 2010, Pages 1073-1086

  Klueh, Ulrike ^a   Liu, Zenghe ^b   Feldman, Ben ^b   Kreutzer, Don ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Angiogenesis; Biosensor; Diabetes; Fibrosis; Inflammation; Interleukin 1; Interleukin 1 receptor antagonist; Tissue responses

Indexed keywords

GLUCOSE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

ANIMAL; ANIMAL MODEL; ARTICLE; BIOPSY; C57BL MOUSE; FEMALE; FIBROSIS; GENETIC PROCEDURES; GENETICS; INFLAMMATION; INSTRUMENTATION; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; PATHOLOGY; SKIN; TRANSGENIC MOUSE;

ANIMALS; BIOPSY; BIOSENSING TECHNIQUES; FEMALE; FIBROSIS; GLUCOSE; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, ANIMAL; SKIN;

EID: 79952198318     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400506     Document Type: Conference Paper

References (38)

1. Klueh U, Kaur M, Qiao Y, Kreutzer DL. Critical role of tissue mast cells in controlling long-term glucose sensor function in vivo. Biomaterials. 2010;31(16):4540-51.
2. Klueh U, Liu Z, Ouyang T, Cho B, Feldman B, Henning TP, Kreutzer D. Blood-induced interference of glucose sensor function in vitro: implications for in vivo sensor function. J Diabetes Sci Technol. 2007;1(6):842-9.
3. Klueh U, Kaur M, Montrose DC, Kreutzer DL. Inflammation and glucose sensors: use of dexamethasone to extend glucose sensor function and life span in vivo. J Diabetes Sci Technol. 2007;1(4):496-504.
4. Friedl KE. Corticosteroid modulation of tissue responses to implanted sensors. Diabetes Technol Ther. 2004;6(6):898-901.
5. McGregor VP, Banarer S, Cryer PE. Elevated endogenous cortisol reduces autonomic neuroendocrine and symptom responses to subsequent hypoglycemia. Am J Physiol Endocrinol Metab. 2002;282(4):E770-7.
6. Herbert C, Hettiaratchi A, Webb DC, Thomas PS, Foster PS, Kumar RK. Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma. Clin Exp Allergy. 2008;38(5):847-56.
7. Smith SJ, Piliponsky AM, Rosenhead F, Elchalal U, Nagler A, Levi-Schaffer F. Dexamethasone inhibits maturation, cytokine production and Fc epsilon RI expression of human cord blood-derived mast cells. Clin Exp Allergy. 2002;32(6):906-13.
8. Yi ES, Remick DG, Lim Y, Tang W, Nadzienko CE, Bedoya A, Yin S, Ulich TR. The intratracheal administration of endotoxin: X. Dexamethasone downregulates neutrophil emigration and cytokine expression in vivo. Inflammation. 1996;20(2):165-75.
9. Langereis JD, Oudijk EJ, Schweizer RC, Lammers JW, Koenderman L, Ulfman LH. Steroids induce a disequilibrium of sIL-1Ra and IL-1{beta} synthesis by human neutrophils. Eur Respir J. 2010. Epub ahead of print.
10. Newman SP, Flower RJ, Croxtall JD. Dexamethasone suppression of IL-1 beta-induced cyclooxygenase 2 expression is not mediated by lipocortin-1 in A549 cells. Biochem Biophys Res Commun. 1994;202(2):931-9.
11. Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest. 2003;124(4):1526-32.
12. Hyams JS, Fitzgerald JE, Wyzga N, Muller R, Treem WR, Justinich CJ, Kreutzer DL. Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1995;21(4):419-25.
13. Radema SA, Tytgat GN, van Deventer SJ. In situ detection of interleukin-1 beta and interleukin 8 in biopsy specimens from patients with ulcerative colitis. Adv Exp Med Biol. 1995;371B:1297-9.
14. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis. 2000;59 Suppl 1:i60-4.
15. McIntyre KW, Strepan GJ, Kolinsky KD, Benjamin WR, Plocinski JM, Kaffka KL, Campen CA, Chizzonite RA, Kilian PL. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med. 1991;173(4):931-9.
16. Dinarello CA. Blocking interleukin-1 in disease. Blood Purif. 1993;11(2):118-27.
17. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand- Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007;67(20):10019-26.
18. Von Biberstein SE, Spiro JD, Lindquist R, Kreutzer DL. Interleukin-1 receptor antagonist in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1996;122(7):751-9.
19. Irikura VM, Lagraoui M, Hirsh D. The epistatic interrelationships of IL-1, IL-1 receptor antagonist, and the type I IL-1 receptor. J Immunol. 2002;169(1):393-8.
20. Klueh U, Liu Z, Cho B, Ouyang T, Feldman B, Henning TP, Kaur M, Kreutzer D. Continuous glucose monitoring in normal mice and mice with prediabetes and diabetes. Diabetes Technol Ther. 2006;8(3):402-12.
21. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A. 1996;93(20):11008-13.
22. Bequette BW. Continuous glucose monitoring: real-time algorithms for calibration, filtering, and alarms. J Diabetes Sci Technol. 2010;4(2):404-18.
23. Dassau E, Cameron F, Lee H, Bequette BW, Zisser H, Jovanovic L, Chase HP, Wilson DM, Buckingham BA, Doyle FJ 3rd. Real-time hypoglycemia prediction suite using continuous glucose monitoring: a safety net for the artificial pancreas. Diabetes Care. 2010;33(6):1249-54.
24. Peifer C, Wagner G, Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr Top Med Chem. 2006;6(2):113-49.
25. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;328(2):106-13.
26. Muzio M, Polentarutti N, Facchetti F, Peri G, Doni A, Sironi M, Transidico P, Salmona M, Introna M, Mantovani A. Characterization of type II intracellular IL-1 receptor antagonist (IL- 1ra3): a depot IL-1ra. Eur J Immunol. 1999;29(3):781-8.
27. Muzio M, Polentarutti N, Sironi M, Poli G, De Gioia L, Introna M, et al. Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist. J Exp Med. 1995;182(2):623-8.
28. Wesche H, Korherr C, Kracht M, Falk W, Resch K, Martin MU. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem. 1997;272(12):7727-31.
29. O'Neill LA. Molecular mechanisms underlying the actions of the pro-inflammatory cytokine interleukin 1. Royal Irish Academy Medal Lecture. Biochem Soc Trans. 1997;25(1):295-302.
30. Rutter JL, Benbow U, Coon CI, Brinckerhoff CE. Cell-type specific regulation of human interstitial collagenase-1 gene expression by interleukin-1 beta (IL-1 beta) in human fibroblasts and BC-8701 breast cancer cells. J Cell Biochem. 1997;66(3):322-36.
31. Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle PA, Blasi F. A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J. 1992;11(1):205-13.
32. Nguyen M, Corless CL, Kräling BM, Tran C, Atha T, Bischoff J, Barsky SH. Vascular expression of E-selectin is increased in estrogen-receptor- negative breast cancer: a role for tumor-cell-secreted interleukin-1 alpha. Am J Pathol. 1997;150(4):1307-14.
33. Rangnekar VV, Waheed S, Davies TJ, Toback FG, Rangnekar VM. Antimitogenic and mitogenic actions of interleukin-1 in diverse cell types are associated with induction of gro gene expression. J Biol Chem. 1991;266(4):2415-22.
34. Sica A, Matsushima K, van Damme J, Wang Y, Polentanitte M, Dejana N, Collotta E, Mantovani A. IL-1 transcriptionally activates the neutrophil chemotactic factor/IL-8 gene in endothelial cells. Immunology. 1990;69(4):548-53.
35. Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 2010;29(2):317-29.
36. Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M, Huszar M, White MR, Dinarello CA, Apte RN. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol. 2009;183(7):4705-14.
37. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity. 2005;23(4):344-6.
38. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol. 2007;37(1):14-6.